Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KOMET phase III trial of selumetinib in adults with NF1 and symptomatic inoperable plexiform neurofibromas
2020-005607-39Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) comparing Selumetinib with Placebo (2 arms). Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on 2020-005607-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005607-39.